Table 1.
Baseline Characteristics of Patients Studied
| R−/D+ n = 15 |
R+/D+ n = 57 |
R+/D− n = 45 |
|
|---|---|---|---|
| Gender | |||
| Men | 11(73.3) | 26 (45.6) | 24 (53.3) |
| Women | 4 (26.7) | 31 (54.4) | 21 (46.7) |
| Underlying disease type | |||
| MDS | 2 (13.3) | 9 (15.8) | 7 (15.6) |
| CLL/CML | 3 (20.0) | 11 (19.3) | 7 (15.6) |
| HD/NHL | 7 (46.7) | 16 (28.1) | 14 (31.1) |
| ALL/ANLL | 3 (20.0) | 21 (36.8) | 17 (37.8) |
| Disease state at transplant* | |||
| Relapse | 3 (21.4) | 9 (15.8) | 8 (18.2) |
| Partial remission | 5 (35.7) | 17 (29.8) | 16 (36.4) |
| Complete remission | 6 (42.9) | 31 (54.4) | 20 (45.4) |
| Donor type | |||
| MRD | 8 (53.3) | 35 (61.4) | 19 (42.2) |
| Haplo/PMRD | 1 (6.7) | 5 (8.8) | 2 (4.4) |
| URD | 6 (40.0) | 17 (29.8) | 24 (53.3) |
| Age | 55 (27–64) | 56 (23–66) | 58 (21–67) |
| Follow-up time (days) | 437 | 518 | 504 |
MDS indicates myelodysplastic syndrome; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; HD, Hodgkin’s disease; NHL, non-Hodgkin’s lymphoma; ALL, acute lymphocytic leukemia; ANLL, acute nonlymphocytic leukemia; MRD, matched related donor; PMRD, partially matched related donor: URD, unrelated donor. Patients undergoing HCT following a TLI/ATG-based, nonmyeloablative preparative regimen were analyzed for pretransplant characteristics by CMV serogroup. For each variable presented the number of patients in each group is followed by parenthesis indicating percentage for each serogroup category. Age is expressed in median years followed by range, and follow-up time is expressed as median days. No categories were significantly different between serogroups by Fisher exact for categoric variables and Mann-Whitney U test for continuous variables. The Fisher exact test was used for disease type, relapse status at transplant, and donor type.
Two patients (one R+/D− and 1 R−/D+) had missing information regarding disease state at transplant.